Proceedings from Duke resistant hypertension think tank.

[1]  Deepak L. Bhatt,et al.  Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. , 2014, International journal of cardiology.

[2]  Michael Böhm,et al.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study , 2014, The Lancet.

[3]  Michael Böhm,et al.  2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension , 2014, Blood pressure.

[4]  John Chalmers,et al.  Clinical Practice Guidelines for the Management of Hypertension in the Community , 2014, Journal of clinical hypertension.

[5]  R. Haynes,et al.  Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.

[6]  A. Schutte,et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.

[7]  C. Hamm,et al.  Influence of renal sympathetic denervation on quality of life. , 2013, Journal of interventional cardiology.

[8]  M. Böhm,et al.  Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  R. Brook,et al.  Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network , 2013, Hypertension.

[10]  D. Francis,et al.  Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report , 2013, Heart.

[11]  Mitchell W Krucoff,et al.  Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). , 2013, American heart journal.

[12]  A. Go,et al.  Improved blood pressure control associated with a large-scale hypertension program. , 2013, JAMA.

[13]  R. Conwit,et al.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial , 2013, The Lancet.

[14]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.

[15]  B. Egan,et al.  Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients: National Health and Nutrition Examination Surveys 1988–2010 , 2013, Circulation.

[16]  L. Tarasenko,et al.  Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010 , 2013, BMC Nephrology.

[17]  C. Tsioufis,et al.  Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial , 2013, European heart journal.

[18]  Deepak L. Bhatt,et al.  Renal Sympathetic Denervation Therapy for Resistant Hypertension: A Contemporary Synopsis and Future Implications , 2013, Circulation. Cardiovascular interventions.

[19]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[20]  Deepak L. Bhatt,et al.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. , 2012, European heart journal.

[21]  H. Krum,et al.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.

[22]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[23]  H. Krum,et al.  Health-Related Quality of Life After Renal Denervation in Patients With Treatment-Resistant Hypertension , 2012, Hypertension.

[24]  M. Carroll,et al.  Hypertension among adults in the United States, 2009-2010. , 2012, NCHS data brief.

[25]  Deepak L. Bhatt,et al.  Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial , 2012, Clinical cardiology.

[26]  P. Levy,et al.  Relationship of Resistant Hypertension and Treatment Outcomes With Total Arterial Compliance in a Predominantly African American Hypertensive Cohort , 2012, Journal of clinical hypertension.

[27]  Sergey Goryachev,et al.  Implementation of the Department of Veterans Affairs' first point-of-care clinical trial , 2012, J. Am. Medical Informatics Assoc..

[28]  E. Peterson,et al.  Hypertension Control Among Patients Followed by Cardiologists , 2012, Circulation. Cardiovascular quality and outcomes.

[29]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[30]  S. Oparil,et al.  Refractory Hypertension: Definition, Prevalence, and Patient Characteristics , 2012, Journal of clinical hypertension.

[31]  W. Elliott.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2012 .

[32]  H. Krum,et al.  Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension: One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial , 2012, Circulation.

[33]  Donald M Berwick,et al.  The "Million Hearts" initiative--preventing heart attacks and strokes. , 2011, The New England journal of medicine.

[34]  B. Egan,et al.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2011, Circulation.

[35]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[36]  E. Ford.  Trends in Mortality From All Causes and Cardiovascular Disease Among Hypertensive and Nonhypertensive Adults in the United States , 2011, Circulation.

[37]  Leonard W. D'Avolio,et al.  A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen , 2011, Clinical Trials (London, England).

[38]  H. Makani,et al.  Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. , 2011, Journal of the American College of Cardiology.

[39]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[40]  Jens Jordan,et al.  Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.

[41]  T. Ogihara,et al.  Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study , 2010, Hypertension.

[42]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[43]  J. Staessen,et al.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2009, The Lancet.

[44]  P Michael Ho,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.

[45]  Cyrus Mehta,et al.  Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.

[46]  石井當男.  Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) , 2008, Hypertension Research.

[47]  GuidoGrassi,et al.  Adrenergic, Metabolic, and Reflex Abnormalities in Reverse and Extreme Dipper Hypertensives , 2008 .

[48]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[49]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[50]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[51]  Jan A. Staessen,et al.  Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension , 2008, Hypertension.

[52]  W. J. Elliott,et al.  Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review , 2008 .

[53]  N. Chapman,et al.  Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension , 2007, Hypertension.

[54]  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension , 2007 .

[55]  G. Bakris,et al.  Efficacy of a Once‐Daily Formulation of Carvedilol for the Treatment of Hypertension , 2006, Journal of clinical hypertension.

[56]  G. Bergus,et al.  Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure , 2006, Hypertension.

[57]  Yutaka Imai,et al.  Prognostic Significance for Stroke of a Morning Pressor Surge and a Nocturnal Blood Pressure Decline: The Ohasama Study , 2006, Hypertension.

[58]  H. Black,et al.  Resistant hypertension revisited: a comparison of two university-based cohorts. , 2005, American journal of hypertension.

[59]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[60]  EuroPCR.  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. , 2005 .

[61]  T Fahey,et al.  Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings (Review) , 2018 .

[62]  T. Fahey,et al.  How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. , 2004, Archives of internal medicine.

[63]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[64]  D. Calhoun,et al.  Efficacy of low-dose spironolactone in subjects with resistant hypertension. , 2003, American journal of hypertension.

[65]  N. Hollenberg,et al.  Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. , 2003, Archives of internal medicine.

[66]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[67]  E. Schiffrin,et al.  Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. , 2003, Archives of internal medicine.

[68]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[69]  P. Burkhart,et al.  Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[70]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[71]  D. Calhoun,et al.  Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension , 2002, Hypertension.

[72]  G Parati,et al.  Ambulatory Blood Pressure Monitoring and Organ Damage , 2000, Hypertension.

[73]  A. Jula,et al.  Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. , 1999, Hypertension.

[74]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[75]  W. Applegate.  Quality of life during antihypertensive treatment. Lessons from the Systolic Hypertension in the Elderly Program. , 1998, American journal of hypertension.

[76]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[77]  Giuseppe Mancia,et al.  Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy , 1997 .

[78]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[79]  G Mancia,et al.  Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. , 1997, Circulation.

[80]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[81]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[82]  D. Reda,et al.  Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. , 1995, Journal of human hypertension.

[83]  T. Greene,et al.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.

[84]  W. Applegate,et al.  Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. , 1994, Archives of internal medicine.

[85]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[86]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[87]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[88]  S. Klahr.  The modification of diet in renal disease study. , 1989, The New England journal of medicine.

[89]  R. Tarazi.  Management of the patient with resistant hypertension. , 1981, Hospital practice.

[90]  R. Tarazi,et al.  Resistant hypertension: diagnosis and management. , 1978, Annals of internal medicine.